Baudax Bio, Inc. Common Stock
BXRX
BXRX was delisted on the 15th of November, 2023.
10 hedge funds and large institutions have $73.2K invested in Baudax Bio, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 11 closing their positions.
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
50% less funds holding
Funds holding: 20 → 10 (-10)
79% less capital invested
Capital invested by funds: $352K → $73.2K (-$279K)
91% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$113K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$6.45K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$820 |
| 4 |
Wells Fargo
San Francisco,
California
|
+$12 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$108K |
| 2 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$66K |
| 3 |
Renaissance Technologies
New York
|
-$59K |
| 4 |
VF
Virtu Financial
New York
|
-$27K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$16K |
BXRX Hedge Fund Activity: Q4 2022 in Review
10 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Baudax Bio, Inc. Common Stock (BXRX) for Q4 2022, worth a combined $73.2K — down 79% from $352K a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of BXRX and 1 opened new positions — a net loss of 10 holders — while 4 trimmed existing stakes and 3 added.
The largest buyer was State Street, opening a new position worth an estimated $113K. The largest seller was Sabby Management, exiting entirely with an estimated $108K sold.
- 10 institutional investors held Baudax Bio, Inc. Common Stock (BXRX) as of Q4 2022, down from 20 in Q3 2022.
- Funds reported $73.2K of Baudax Bio, Inc. Common Stock stock for Q4 2022, down 79% quarter-over-quarter.
- 1 fund opened new Baudax Bio, Inc. Common Stock positions in Q4 2022 and 11 closed out, a net change of -10 holders.
- The largest Baudax Bio, Inc. Common Stock buyer in Q4 2022 was State Street, an estimated $113K added.
- The largest Baudax Bio, Inc. Common Stock seller in Q4 2022 was Sabby Management, an estimated $108K sold.
Based on aggregated 13F filings for Q4 2022.